{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:03:15Z","timestamp":1772856195862,"version":"3.50.1"},"reference-count":218,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.intimp.2020.107051","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T02:15:13Z","timestamp":1601345713000},"page":"107051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies"],"prefix":"10.1016","volume":"92","author":[{"given":"Soheila","family":"Molaei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoomeh","family":"Dadkhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Asghariazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiman","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Safarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0005","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/v12020194","article-title":"Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections","volume":"12","author":"Schwartz","year":"2020","journal-title":"Viruses"},{"issue":"10224","key":"10.1016\/j.intimp.2020.107051_b0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2020.107051_b0015","doi-asserted-by":"crossref","unstructured":"J.Y. Lee, et al., The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015, BMC Infectious Diseases 17(1) (2017) 498.","DOI":"10.1186\/s12879-017-2576-5"},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/dyaa033","article-title":"MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?","volume":"49","author":"Peeri","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.intimp.2020.107051_b0025","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b0030","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ccm.2016.11.007","article-title":"Epidemic and emerging coronaviruses (severe acute respiratory syndrome and middle east respiratory syndrome)","volume":"38","author":"Hui","year":"2017","journal-title":"Clin. Chest Med."},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","article-title":"The SARS-CoV-2 vaccine pipeline: An overview","author":"Chen","year":"2020","journal-title":"Curr. Trop. Med. Rep."},{"issue":"8","key":"10.1016\/j.intimp.2020.107051_b0045","first-page":"216","article-title":"Update: public health response to the coronavirus disease 2019 outbreak\u2014United States, February 24, 2020. MMWR. Morbidity and mortality weekly report","volume":"69","author":"Jernigan","year":"2020","journal-title":"CDC"},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0050","first-page":"1","article-title":"Novel coronavirus COVID-19: an overview for emergency clinicians","volume":"22","author":"Giwa","year":"2020","journal-title":"Emerg. Med. Pract."},{"key":"10.1016\/j.intimp.2020.107051_b0055","unstructured":"WHO, 2020."},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01721-16","article-title":"The conserved coronavirus macrodomain promotes virulence and suppresses the innate immune response during severe acute respiratory syndrome coronavirus infection","volume":"7","author":"Fehr","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.intimp.2020.107051_b0065","series-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","author":"Liu","year":"2020"},{"issue":"4","key":"10.1016\/j.intimp.2020.107051_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00524-13","article-title":"Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles","volume":"4","author":"Angelini","year":"2013","journal-title":"mBio"},{"issue":"13","key":"10.1016\/j.intimp.2020.107051_b0075","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1073\/pnas.0508200103","article-title":"Discovery of an RNA virus 3\u2032\u2192 5\u2032 exoribonuclease that is critically involved in coronavirus RNA synthesis","volume":"103","author":"Minskaia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0080","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/jcp.27155","article-title":"Modulation of the immune response by Middle East respiratory syndrome coronavirus","volume":"234","author":"Shokri","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.intimp.2020.107051_b0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.virusres.2014.11.019","article-title":"Coronavirus nonstructural protein 1: Common and distinct functions in the regulation of host and viral gene expression","volume":"202","author":"Narayanan","year":"2015","journal-title":"Virus Res."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088716","article-title":"Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?","volume":"9","author":"Faure","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.intimp.2020.107051_b0095","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1128\/JVI.03571-13","article-title":"Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2\u2032-O-methyltransferase activity","volume":"88","author":"Menachery","year":"2014","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0100","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"28","key":"10.1016\/j.intimp.2020.107051_b0105","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre-and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"9","key":"10.1016\/j.intimp.2020.107051_b0110","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/JCM.01368-15","article-title":"Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia","volume":"53","author":"Muth","year":"2015","journal-title":"J. Clin. Microbiol."},{"issue":"19","key":"10.1016\/j.intimp.2020.107051_b0115","doi-asserted-by":"crossref","first-page":"11297","DOI":"10.1128\/JVI.01498-14","article-title":"Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat","volume":"88","author":"Corman","year":"2014","journal-title":"J. Virol."},{"issue":"29","key":"10.1016\/j.intimp.2020.107051_b0120","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.intimp.2020.107051_b0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.virusres.2014.05.026","article-title":"Coronavirus reverse genetic systems: Infectious clones and replicons","volume":"189","author":"Almaz\u00e1n","year":"2014","journal-title":"Virus Res."},{"issue":"23","key":"10.1016\/j.intimp.2020.107051_b0130","doi-asserted-by":"crossref","first-page":"13769","DOI":"10.1128\/JVI.02232-14","article-title":"Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness","volume":"88","author":"Sui","year":"2014","journal-title":"J. Virol."},{"issue":"44","key":"10.1016\/j.intimp.2020.107051_b0135","doi-asserted-by":"crossref","first-page":"15748","DOI":"10.1073\/pnas.0403812101","article-title":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus","volume":"101","author":"Jeffers","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.intimp.2020.107051_b0140","article-title":"Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China","author":"Wu","year":"2020","journal-title":"BioRvix"},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0145","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00705-019-04488-3","article-title":"A recombinant infectious bronchitis virus from a chicken with a spike gene closely related to that of a turkey coronavirus","volume":"165","author":"Wang","year":"2020","journal-title":"Arch. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0150","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13550280490280292","article-title":"Coronavirus replication and pathogenesis: implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development","volume":"10","author":"Navas-Mart\u00edn","year":"2004","journal-title":"J. Neurovirology"},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0155","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1074\/jbc.C300520200","article-title":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2","volume":"279","author":"Wong","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0160","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"issue":"11","key":"10.1016\/j.intimp.2020.107051_b0165","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3201\/eid1911.131172","article-title":"Middle East respiratory syndrome coronavirus in bats, Saudi Arabia","volume":"19","author":"Memish","year":"2013","journal-title":"Emerg. Infect. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2020.107051_b0170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tics.2013.08.001","article-title":"Bridging animal and human models of exercise-induced brain plasticity","volume":"17","author":"Voss","year":"2013","journal-title":"Trends Cognitive Sci."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the Coronavirus: 2019-nCoV","volume":"12","author":"Gralinski","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2020.107051_b0180","series-title":"Coronaviruses","first-page":"1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","author":"Fehr","year":"2015"},{"key":"10.1016\/j.intimp.2020.107051_b0185","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv. Virus Res."},{"issue":"9","key":"10.1016\/j.intimp.2020.107051_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060226","article-title":"SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum","volume":"6","author":"Knoops","year":"2008","journal-title":"PLoS Biol."},{"issue":"7461","key":"10.1016\/j.intimp.2020.107051_b0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature12328","article-title":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26","volume":"500","author":"Lu","year":"2013","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.intimp.2020.107051_b0200","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/CM9.0000000000000774","article-title":"Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients","volume":"133","author":"Ling","year":"2020","journal-title":"Chin. Med. J."},{"issue":"9","key":"10.1016\/j.intimp.2020.107051_b0205","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0210","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"issue":"45","key":"10.1016\/j.intimp.2020.107051_b0215","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1016\/j.vaccine.2014.08.058","article-title":"Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB\/c mice","volume":"32","author":"Kim","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.107051_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.107051_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: origin, transmission, and characteristics of human coronaviruses","author":"Shereen","year":"2020","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.intimp.2020.107051_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imr.12109","article-title":"Immunity to viruses","volume":"255","author":"Braciale","year":"2013","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0235","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.coviro.2012.04.004","article-title":"SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon","volume":"2","author":"Totura","year":"2012","journal-title":"Curr. Opin. Virology"},{"key":"10.1016\/j.intimp.2020.107051_b0240","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2014.12.012","article-title":"Viral RNA detection by RIG-I-like receptors","volume":"32","author":"Yoneyama","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2020.107051_b0245","first-page":"1","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","author":"Rehwinkel","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.107051_b0250","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/9781555819194.ch24","article-title":"Toll-like receptor signaling and its inducible proteins","author":"Satoh","year":"2017","journal-title":"Myeloid Cells in Health and Disease: A Synthesis"},{"key":"10.1016\/j.intimp.2020.107051_b0255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.intimp.2018.03.002","article-title":"Toll-like receptors in immunity and inflammatory diseases: Past, present, and future","volume":"59","author":"Vijay","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0260","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1042\/BC20040058","article-title":"Virus factories: associations of cell organelles for viral replication and morphogenesis","volume":"97","author":"Novoa","year":"2005","journal-title":"Biol. Cell"},{"issue":"12","key":"10.1016\/j.intimp.2020.107051_b0265","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.virusres.2007.03.015","article-title":"SARS coronavirus and innate immunity","volume":"133","author":"Frieman","year":"2008","journal-title":"Virus Res."},{"issue":"10","key":"10.1016\/j.intimp.2020.107051_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000636","article-title":"Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice","volume":"5","author":"Zhao","year":"2009","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008729","article-title":"Dynamic innate immune responses of human bronchial epithelial cells to severe acute respiratory syndrome-associated coronavirus infection","volume":"5","author":"Yoshikawa","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.107051_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","author":"Vabret","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0290","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2172-10-35","article-title":"Toll-like receptors, chemokine receptors and death receptor ligands responses in SARS coronavirus infected human monocyte derived dendritic cells","volume":"10","author":"Law","year":"2009","journal-title":"BMC Immunology"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.107051_b0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virusres.2009.01.005","article-title":"SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-\u03baB pathway in human monocyte macrophages in vitro","volume":"142","author":"Dosch","year":"2009","journal-title":"Virus Res."},{"key":"10.1016\/j.intimp.2020.107051_b0300","series-title":"Seminars in Immunopathology","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","author":"Channappanavar","year":"2017"},{"key":"10.1016\/j.intimp.2020.107051_b0305","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fmicb.2014.00296","article-title":"Coronavirus infection, ER stress, apoptosis and innate immunity","volume":"5","author":"Fung","year":"2014","journal-title":"Front. Microbiol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0310","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.coviro.2012.04.002","article-title":"How respiratory viruses overcome mucosal defenses and exploit the unique environment of the respiratory tract","volume":"2","author":"Al von Messling","year":"2012","journal-title":"Curr. Opin. Virol."},{"issue":"15","key":"10.1016\/j.intimp.2020.107051_b0315","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine","volume":"88","author":"Iwata-Yoshikawa","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.107051_b0320","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fgene.2020.00641","article-title":"Neutrophils, crucial, or harmful immune cells involved in coronavirus infection: a bioinformatics study","volume":"11","author":"Hemmat","year":"2020","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b0325","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: Neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.intimp.2020.107051_b0330","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.09.28","article-title":"Insights into the immuno-pathogenesis of acute respiratory distress syndrome","volume":"7","author":"Wong","year":"2019","journal-title":"Ann. Translational Med."},{"key":"10.1016\/j.intimp.2020.107051_b0335","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2017.00550","article-title":"A role for neutrophils in viral respiratory disease","volume":"8","author":"Camp","year":"2017","journal-title":"Front. Immunol."},{"issue":"10223","key":"10.1016\/j.intimp.2020.107051_b0340","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"The Lancet"},{"issue":"10223","key":"10.1016\/j.intimp.2020.107051_b0345","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.107051_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19","author":"Li","year":"2020","journal-title":"J. Pharm. Anal."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0355","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coviro.2012.04.006","article-title":"Recent insights into pulmonary repair following virus-induced inflammation of the respiratory tract","volume":"2","author":"Gorski","year":"2012","journal-title":"Curr. Opin. Virology"},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0360","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-11-82","article-title":"Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus","volume":"11","author":"Yip","year":"2014","journal-title":"Virology J."},{"key":"10.1016\/j.intimp.2020.107051_b0370","first-page":"1","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.107051_b0375","first-page":"1","article-title":"The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development","author":"Wang","year":"2020","journal-title":"J. Clin. Transl. Sci."},{"key":"10.1016\/j.intimp.2020.107051_b0380","article-title":"The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement","author":"Quinlan","year":"2020","journal-title":"IMMUNITY-D-20-00389"},{"key":"10.1016\/j.intimp.2020.107051_b0385","article-title":"Reinfection could not occur in SARS-CoV-2 infected rhesus macaques","author":"Bao","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.intimp.2020.107051_b0390","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3389\/fimmu.2020.01441","article-title":"Immune response, inflammation, and the clinical spectrum of COVID-19","volume":"11","author":"Garc\u00eda","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.107051_b0395","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01526-2020","article-title":"Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients","author":"Yu","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2020.107051_b0400","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3389\/fimmu.2018.00320","article-title":"Host immune response to influenza A virus infection","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0405","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/cmi.2010.24","article-title":"Understanding the development and function of T follicular helper cells","volume":"7","author":"Nurieva","year":"2010","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2020.107051_b0410","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fimmu.2019.00249","article-title":"Molecular basis of the differentiation and function of virus specific follicular helper CD4+ T cells","volume":"10","author":"Huang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2020.107051_b0415","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/954602","article-title":"Cytotoxic CD4 T cells in antiviral immunity","volume":"2011","author":"Marshall","year":"2011","journal-title":"Biomed Res. Int."},{"issue":"12","key":"10.1016\/j.intimp.2020.107051_b0420","doi-asserted-by":"crossref","first-page":"6792","DOI":"10.1128\/JVI.07172-11","article-title":"Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection","volume":"86","author":"Brown","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0425","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.4049\/jimmunol.177.5.2888","article-title":"CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch","volume":"177","author":"Brown","year":"2006","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0430","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/cmi.2013.61","article-title":"Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain","volume":"11","author":"Siu","year":"2014","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2020.107051_b0435","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030802","article-title":"Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling","volume":"7","author":"Sun","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.107051_b0445","first-page":"1","article-title":"COVID-19 and the elderly: insights into pathogenesis and clinical decision-making","author":"Perrotta","year":"2020","journal-title":"Aging Clin. Exp. Res."},{"key":"10.1016\/j.intimp.2020.107051_b0450","doi-asserted-by":"crossref","unstructured":"C.Y. Yong, et al., Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus, 10 (2019) 1781.","DOI":"10.3389\/fmicb.2019.01781"},{"key":"10.1016\/j.intimp.2020.107051_b0455","doi-asserted-by":"crossref","unstructured":"A. Roberts, et al., Animal models and vaccines for SARS-CoV infection. 133(1) (2008) 20\u201332.","DOI":"10.1016\/j.virusres.2007.03.025"},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0460","first-page":"652","volume":"24","author":"Spruth","year":"2006","journal-title":"A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses."},{"key":"10.1016\/j.intimp.2020.107051_b0465","doi-asserted-by":"crossref","unstructured":"D. Qu, et al., Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. 23(7) (2005) 924\u2013931.","DOI":"10.1016\/j.vaccine.2004.07.031"},{"key":"10.1016\/j.intimp.2020.107051_b0470","doi-asserted-by":"crossref","unstructured":"J. Zhou, et al., Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. 23(24) (2005) 3202\u20133209.","DOI":"10.1016\/j.vaccine.2004.11.075"},{"key":"10.1016\/j.intimp.2020.107051_b0475","doi-asserted-by":"crossref","unstructured":"W.-p. Kong, et al., Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization. 79(22) (2005) 13915\u201313923.","DOI":"10.1128\/JVI.79.22.13915-13923.2005"},{"key":"10.1016\/j.intimp.2020.107051_b0480","doi-asserted-by":"crossref","unstructured":"A. Roberts, et al., Immunogenicity and protective efficacy in mice and hamsters of a \u03b2-propiolactone inactivated whole virus SARS-CoV vaccine, 23(5) (2010) 509\u2013519.","DOI":"10.1089\/vim.2010.0028"},{"key":"10.1016\/j.intimp.2020.107051_b0485","doi-asserted-by":"crossref","unstructured":"R.H. See, et al., Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus, 87(3) (2006) 641\u2013650.","DOI":"10.1099\/vir.0.81579-0"},{"key":"10.1016\/j.intimp.2020.107051_b0490","doi-asserted-by":"crossref","unstructured":"M. Bolles, et al., A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge 85(23) (2011) 12201\u201312215.","DOI":"10.1128\/JVI.06048-11"},{"key":"10.1016\/j.intimp.2020.107051_b0495","doi-asserted-by":"crossref","unstructured":"C.-T. Tseng, et al., Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus, 7(4), 2012.","DOI":"10.1371\/journal.pone.0035421"},{"key":"10.1016\/j.intimp.2020.107051_b0500","doi-asserted-by":"crossref","unstructured":"S. Xiong, et al., Immunogenicity of SARS inactivated vaccine in BALB\/c mice. 95(2) (2004) 139\u2013143.","DOI":"10.1016\/j.imlet.2004.06.014"},{"key":"10.1016\/j.intimp.2020.107051_b0505","doi-asserted-by":"crossref","unstructured":"Y., He, et al., Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry, 325(2) (2004) 445\u2013452.","DOI":"10.1016\/j.bbrc.2004.10.052"},{"key":"10.1016\/j.intimp.2020.107051_b0510","doi-asserted-by":"crossref","unstructured":"K.G. Lokugamage, et al., Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. 26(6) (2008) 797\u2013808.","DOI":"10.1016\/j.vaccine.2007.11.092"},{"key":"10.1016\/j.intimp.2020.107051_b0515","doi-asserted-by":"crossref","unstructured":"M.E. Darnell, et al., Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets, 196(9) (2007) 1329\u20131338.","DOI":"10.1086\/522431"},{"key":"10.1016\/j.intimp.2020.107051_b0520","doi-asserted-by":"crossref","unstructured":"R.H. See, et al., Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. 89(9) (2008) 2136\u20132146.","DOI":"10.1099\/vir.0.2008\/001891-0"},{"key":"10.1016\/j.intimp.2020.107051_b0525","doi-asserted-by":"crossref","unstructured":"Y. Honda-Okubo, et al., Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. 89(6) (2015) 2995\u20133007.","DOI":"10.1128\/JVI.02980-14"},{"key":"10.1016\/j.intimp.2020.107051_b0530","doi-asserted-by":"crossref","unstructured":"Roper, R.L. and K.E.J.E.r.o.v. Rehm, SARS vaccines: where are we? 2009. 8(7): p. 887-898.","DOI":"10.1586\/erv.09.43"},{"key":"10.1016\/j.intimp.2020.107051_b0535","doi-asserted-by":"crossref","unstructured":"Y. Deng, et al., Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. 7(1) (2018) 1\u201310.","DOI":"10.1038\/s41426-018-0056-7"},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0540","doi-asserted-by":"crossref","first-page":"e02040","DOI":"10.1128\/JVI.02040-16","article-title":"One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus","volume":"91","author":"Wirblich","year":"2017","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0545","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1128\/JVI.03427-14","article-title":"Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease","volume":"89","author":"Agrawal","year":"2015","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0550","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/135965350701200702","article-title":"Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine","volume":"12","author":"Lin","year":"2007","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0555","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0560","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14760584.2015.966085","article-title":"Vaccine adjuvant uses of poly-IC and derivatives","volume":"14","author":"Martins","year":"2015","journal-title":"Expert Rev. Vaccines"},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b0565","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/jir.2014.0034","article-title":"dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects","volume":"34","author":"Chattopadhyay","year":"2014","journal-title":"J. Interferon Cytokine Res."},{"issue":"D1","key":"10.1016\/j.intimp.2020.107051_b0570","doi-asserted-by":"crossref","first-page":"D1005","DOI":"10.1093\/nar\/gky1120","article-title":"The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019","volume":"47","author":"Buniello","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0575","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00638-15","article-title":"Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection","volume":"6","author":"Totura","year":"2015","journal-title":"MBio"},{"issue":"21","key":"10.1016\/j.intimp.2020.107051_b0580","doi-asserted-by":"crossref","first-page":"11416","DOI":"10.1128\/JVI.01410-12","article-title":"Intranasal treatment with poly (I\u00b7 C) protects aged mice from lethal respiratory virus infections","volume":"86","author":"Zhao","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0585","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2217\/fvl.11.33","article-title":"Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy","volume":"6","author":"Barnard","year":"2011","journal-title":"Future Virology"},{"key":"10.1016\/j.intimp.2020.107051_b0590","unstructured":"P. Mosaddeghi, et al., Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses, 2020."},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0595","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/095632020601700505","article-title":"Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB\/c mice","volume":"17","author":"Barnard","year":"2006","journal-title":"Antiviral Chem. Chemother."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","article-title":"Towards effective COVID-19 vaccines: Updates, perspectives and challenges","volume":"46","author":"Calina","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.intimp.2020.107051_b0605","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2020.107051_b0610","article-title":"DRAFT landscape of COVID-19 candidate vaccines","author":"Organization","year":"2020","journal-title":"World"},{"key":"10.1016\/j.intimp.2020.107051_b0615","unstructured":"S.A. Plotkin, W.A. Orenstein, O. PA., Vaccines. 5th edn ed. Vol. 5th edn. 2008, Philadelphia: Saunders\/Elsevier."},{"key":"10.1016\/j.intimp.2020.107051_b0620","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.04.008","article-title":"Middle East respiratory syndrome vaccines","volume":"47","author":"Perlman","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107051_b0625","doi-asserted-by":"crossref","first-page":"e00650","DOI":"10.1128\/mBio.00650-13","article-title":"Engineering a replication-competent, propagationdefective middle east respiratory syndrome coronavirus as a vaccine candidate","volume":"4","author":"Almazan","year":"2013","journal-title":"MBio"},{"key":"10.1016\/j.intimp.2020.107051_b0630","doi-asserted-by":"crossref","unstructured":"T. Scobey, et al., Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. 110(40) (2013) 16157\u201316162.","DOI":"10.1073\/pnas.1311542110"},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b0635","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2020.107051_b0640","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/nm.2972","article-title":"A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease","volume":"18","author":"Graham","year":"2012","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0645","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1128\/JVI.78.7.3572-3577.2004","article-title":"Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice","volume":"78","author":"Subbarao","year":"2004","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.intimp.2020.107051_b0650","doi-asserted-by":"crossref","first-page":"1005215","DOI":"10.1371\/journal.ppat.1005215","article-title":"Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine","volume":"11","author":"Jimenez-Guardeno","year":"2015","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0655","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ni.1979","article-title":"Ribose 2\u2032-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5","volume":"12","author":"Z\u00fcst","year":"2011","journal-title":"Nat. Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2020.107051_b0660","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1128\/JVI.00304-08","article-title":"A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters","volume":"82","author":"Lamirande","year":"2008","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.intimp.2020.107051_b0665","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.vaccine.2006.11.055","article-title":"Utility of the aged BALB\/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)","volume":"25","author":"Vogel","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.107051_b0670","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virusres.2014.07.024","article-title":"Coronavirus virulence genes with main focus on SARS-CoV envelope gene","volume":"194","author":"DeDiego","year":"2014","journal-title":"Virus Res."},{"key":"10.1016\/j.intimp.2020.107051_b0675","unstructured":"!!! INVALID CITATION !!! (41, 53, 96-105)."},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0680","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"Tang","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"issue":"35","key":"10.1016\/j.intimp.2020.107051_b0685","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"5","key":"10.1016\/j.intimp.2020.107051_b0690","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/infdis\/jiv499","article-title":"Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase","volume":"213","author":"Li","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0695","article-title":"Evaluation of candidate vaccine approaches for MERS-CoV","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0700","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vaccine.2016.11.064","article-title":"The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection","volume":"35","author":"Jiaming","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0705","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/21645515.2017.1296994","article-title":"Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0710","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3390\/v11030212","article-title":"Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas","volume":"11","author":"Adney","year":"2019","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.intimp.2020.107051_b0715","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ebiom.2015.08.031","article-title":"Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge","volume":"2","author":"Lan","year":"2015","journal-title":"EBioMedicine"},{"issue":"46","key":"10.1016\/j.intimp.2020.107051_b0720","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1016\/j.vaccine.2014.08.086","article-title":"Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments\u2014the importance of immunofocusing in subunit vaccine design","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.intimp.2020.107051_b0725","doi-asserted-by":"crossref","first-page":"10777","DOI":"10.1128\/JVI.01756-13","article-title":"Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus","volume":"87","author":"Chen","year":"2013","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.intimp.2020.107051_b0735","doi-asserted-by":"crossref","first-page":"9379","DOI":"10.1128\/JVI.01277-13","article-title":"The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies","volume":"87","author":"Mou","year":"2013","journal-title":"J. Virol."},{"issue":"234","key":"10.1016\/j.intimp.2020.107051_b0740","doi-asserted-by":"crossref","first-page":"234ra59","DOI":"10.1126\/scitranslmed.3008140","article-title":"Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein","volume":"6","author":"Jiang","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2020.107051_b0745","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02357-13","article-title":"Identification of receptor-binding domain in S protein of the novel human coronavirus MERS-CoV as an essential target for vaccine development","author":"Du","year":"2013","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms13473","article-title":"Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines","volume":"7","author":"Du","year":"2016","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.intimp.2020.107051_b0755","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2014.02.004","article-title":"Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines","volume":"32","author":"Ma","year":"2014","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.intimp.2020.107051_b0760","doi-asserted-by":"crossref","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","article-title":"Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets","volume":"78","author":"Weingartl","year":"2004","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0765","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/1573395054065106","article-title":"Rapid response research-SARS coronavirus vaccines and application of processes to other emerging infectious diseases","volume":"1","author":"See","year":"2005","journal-title":"Curr. Immunol. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0770","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2003.09.011","article-title":"Severe acute respiratory syndrome (SARS)\u2014paradigm of an emerging viral infection","volume":"29","author":"Berger","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0775","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","article-title":"Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity","volume":"393","author":"Du","year":"2009","journal-title":"Virology"},{"issue":"17","key":"10.1016\/j.intimp.2020.107051_b0780","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"9427","key":"10.1016\/j.intimp.2020.107051_b0785","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(04)16501-X","article-title":"Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS","volume":"363","author":"Bukreyev","year":"2004","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.intimp.2020.107051_b0790","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1016\/j.vaccine.2007.06.017","article-title":"Intranasal protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice","volume":"25","author":"Hu","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.intimp.2020.107051_b0795","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","article-title":"Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc\u03b3RII-dependent entry into B cells in vitro","volume":"25","author":"Kam","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0800","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/vim.2009.0090","article-title":"A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity","volume":"23","author":"Du","year":"2010","journal-title":"Viral Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0805","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/vim.2012.0076","article-title":"Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates","volume":"26","author":"Li","year":"2013","journal-title":"Viral Immunol."},{"issue":"39\u201340","key":"10.1016\/j.intimp.2020.107051_b0810","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.1016\/j.vaccine.2007.06.047","article-title":"Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses","volume":"25","author":"Huang","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.intimp.2020.107051_b0815","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.3201\/eid1108.041003","article-title":"SARS vaccine protective in mice","volume":"11","author":"Stadler","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0820","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine","volume":"324","author":"He","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2020.107051_b0825","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/dna.2005.24.510","article-title":"Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus","volume":"24","author":"Guo","year":"2005","journal-title":"DNA Cell Biol."},{"issue":"6982","key":"10.1016\/j.intimp.2020.107051_b0830","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","article-title":"A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice","volume":"428","author":"Yang","year":"2004","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.intimp.2020.107051_b0835","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1128\/JCM.43.8.3718-3726.2005","article-title":"Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus","volume":"43","author":"He","year":"2005","journal-title":"J. Clin. Microbiol."},{"issue":"16","key":"10.1016\/j.intimp.2020.107051_b0840","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","article-title":"Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates","volume":"24","author":"Liu","year":"2006","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.intimp.2020.107051_b0845","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1016\/j.vaccine.2009.05.073","article-title":"Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice","volume":"27","author":"Zheng","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.107051_b0850","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-virology-110615-042301","article-title":"Structure, function, and evolution of coronavirus spike proteins","volume":"3","author":"Li","year":"2016","journal-title":"Annu. Rev. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0855","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1134\/S0026893319030154","article-title":"Virus-like particles as an instrument of vaccine production","volume":"53","author":"Syomin","year":"2019","journal-title":"Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0860","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12038-020-00040-7","article-title":"Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus","volume":"45","author":"Mukherjee","year":"2020","journal-title":"J. Biosci."},{"issue":"3","key":"10.1016\/j.intimp.2020.107051_b0865","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Recent developments on COVID-19 and associated human coronavirus disease therapeutic agents, and vaccines","volume":"6","author":"Kahandal","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b0870","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pbi.2004.01.012","article-title":"Prospects for molecular farming in the green alga Chlamydomonas reinhardtii","volume":"7","author":"Franklin","year":"2004","journal-title":"Curr. Opin. Plant Biol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0875","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tim.2017.09.007","article-title":"Transmissible viral vaccines","volume":"26","author":"Bull","year":"2018","journal-title":"Trends Microbiol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0880","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14760584.2016.1106942","article-title":"Self-disseminating vaccines for emerging infectious diseases","volume":"15","author":"Murphy","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2020.107051_b0885","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1590\/S0100-879X2005000400004","article-title":"Recombinant viruses as vaccines against viral diseases","volume":"38","author":"Souza","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"15","key":"10.1016\/j.intimp.2020.107051_b0890","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model","volume":"25","author":"Du","year":"2007","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0895","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","article-title":"SARS vaccine development","volume":"11","author":"Jiang","year":"2005","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b0900","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/v11010059","article-title":"From SARS to MERS, thrusting coronaviruses into the spotlight","volume":"11","author":"Song","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2020.107051_b0905","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.12.007","article-title":"A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization","volume":"150","author":"Liu","year":"2018","journal-title":"Antiviral Res."},{"issue":"11","key":"10.1016\/j.intimp.2020.107051_b0910","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112602","article-title":"Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen","volume":"9","author":"Lan","year":"2014","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220196","article-title":"Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus","volume":"14","author":"Kim","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.107051_b0920","first-page":"1","article-title":"The SARS-CoV-2 vaccine pipeline: an overview","author":"Chen","year":"2020","journal-title":"Curr. Tropical Med. Rep."},{"issue":"50","key":"10.1016\/j.intimp.2020.107051_b0925","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.107051_b0930","unstructured":"Vaxart. PipelineReview.com. Vaxart Announces Initiation of Coronavirus Vaccine Program. 2020 [cited 2020 January 31]; Available from: https:\/\/ investors.vaxart.com\/news-releases\/news-release-details\/vaxart-announcesinitiation-coronavirus-vaccine-program; Accessed on: 09.02.2020."},{"key":"10.1016\/j.intimp.2020.107051_b0935","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341389. A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV). 2020."},{"key":"10.1016\/j.intimp.2020.107051_b0940","unstructured":"https:\/\/www.trialsitenews.com\/cansino-biologics-ad5-ncov-the-first-covid-19-vaccine-to-phase-ii-clinical-trials\/. CanSino Biologics\u2019 Ad5-nCoV the First COVID-19 Vaccine to Phase II Clinical Trials, 2020."},{"issue":"9\u201310","key":"10.1016\/j.intimp.2020.107051_b0945","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0264-410X(99)00271-6","article-title":"DNA and RNA-based vaccines: principles, progress and prospects","volume":"18","author":"Leitner","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.107051_b0950","doi-asserted-by":"crossref","first-page":"44875","DOI":"10.1038\/srep44875","article-title":"Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein","volume":"7","author":"Al-Amri","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2020.107051_b0955","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0952-7915(00)00118-7","article-title":"DNA vaccines: a key for inducing long-term cellular immunity","volume":"12","author":"Gurunathan","year":"2000","journal-title":"Curr. Opin. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2020.107051_b0960","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/erv.09.43","article-title":"SARS vaccines: where are we?","volume":"8","author":"Roper","year":"2009","journal-title":"Expert Rev. Vaccines"},{"issue":"16","key":"10.1016\/j.intimp.2020.107051_b0965","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.vaccine.2007.01.032","article-title":"Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL\/hu mouse models","volume":"25","author":"Okada","year":"2007","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.intimp.2020.107051_b0970","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.vaccine.2007.05.025","article-title":"Induction of T-cell response by a DNA vaccine encoding a novel HLA-A* 0201 severe acute respiratory syndrome coronavirus epitope","volume":"25","author":"Cheung","year":"2007","journal-title":"Vaccine"},{"issue":"301","key":"10.1016\/j.intimp.2020.107051_b0975","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7462","article-title":"A synthetic consensus anti\u2013spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates","volume":"7","author":"Muthumani","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2020.107051_b0980","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.virusres.2014.11.013","article-title":"Receptor-binding domain-based subunit vaccines against MERS-CoV","volume":"202","author":"Zhang","year":"2015","journal-title":"Virus Res."},{"issue":"16","key":"10.1016\/j.intimp.2020.107051_b0990","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.vaccine.2017.02.063","article-title":"DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice","volume":"35","author":"Chi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2020.107051_b0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102743","article-title":"Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development","author":"Kim","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2020.107051_b1000","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fmicb.2019.01781","article-title":"Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus","volume":"10","author":"Yong","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.intimp.2020.107051_b1005","first-page":"1","article-title":"Vaccines for SARS-CoV-2: lessons from other coronavirus strains","author":"Padron-Regalado","year":"2020","journal-title":"Infect. Dis. Therapy"},{"key":"10.1016\/j.intimp.2020.107051_b1010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41573-020-00151-8","article-title":"The COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.intimp.2020.107051_b1015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107051_b1020","unstructured":"C. Biopharmaceuticals, Clover initiates development of recombinant subunit-trimer vaccine for wuhan coronavirus (2019-ncov), 2020."},{"key":"10.1016\/j.intimp.2020.107051_b1025","unstructured":"fudan.edu.cn. Towards an effective mRNA vaccine against 2019-nCoV. 2020 [cited 2020 7 MAR]; Available from: https:\/\/www.fudan.edu.cn\/en\/2020\/0307\/c344a104281\/page.htm."},{"key":"10.1016\/j.intimp.2020.107051_b1030","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b1035","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/bit.24493","article-title":"Vaccine process technology","volume":"109","author":"Josefsberg","year":"2012","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.intimp.2020.107051_b1040","unstructured":"businesswire. Medicago Announces Production of a Viable Vaccine Candidate for COVID-19. 2020 [cited 2020 MAR 12]; Available from: https:\/\/www.businesswire.com\/news\/home\/20200312005345\/en\/."},{"issue":"4","key":"10.1016\/j.intimp.2020.107051_b1045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.107051_b1050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2006100","article-title":"Spread of SARS-CoV-2 in the Icelandic population","author":"Gudbjartsson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.107051_b1055","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus","author":"Korber","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b9000","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.virol.2004.04.017","article-title":"SARS corona virus peptides recognized by antibodies in the sera of convalescent cases","volume":"324","author":"Guo","year":"2004","journal-title":"Virology"},{"issue":"17","key":"10.1016\/j.intimp.2020.107051_b9005","doi-asserted-by":"crossref","first-page":"e00710","DOI":"10.1128\/JVI.00710-18","article-title":"Combination attenuation offers strategy for live attenuated coronavirus vaccines","volume":"92","author":"Menachery","year":"2018","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107051_b9010","first-page":"31","article-title":"SARS CoV subunit vaccine: antibodymediated neutralisation and enhancement","volume":"18","author":"Jaume","year":"2012","journal-title":"Mediccine"},{"issue":"1","key":"10.1016\/j.intimp.2020.107051_b9015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/JVI.02009-15","article-title":"Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease","volume":"90","author":"Tao","year":"2016","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/j.intimp.2020.107051_b9020","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1128\/JVI.01815-15","article-title":"A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform","volume":"89","author":"Malczyk","year":"2015","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107051_b9025","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00346-17","article-title":"Middle east respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis","volume":"2","author":"Menachery","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.intimp.2020.107051_b9030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2018.05.028","article-title":"Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model","volume":"521","author":"Bodmer","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.intimp.2020.107051_b9035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2016.10.005","article-title":"A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection","volume":"499","author":"Tai","year":"2016","journal-title":"Virology"},{"issue":"14","key":"10.1016\/j.intimp.2020.107051_b9040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.vaccine.2018.02.065","article-title":"Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen","volume":"36","author":"Nyon","year":"2018","journal-title":"Vaccine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920322050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920322050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:25:26Z","timestamp":1761585926000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920322050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":218,"alternative-id":["S1567576920322050"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107051","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107051"}}